Robert Motzer MD
@motzermd
Followers
2K
Following
846
Media
2
Statuses
133
Jack and Dorothy Byrne Chair in Clinical Oncology @sloan_kettering
New York, NY
Joined November 2018
RT @brian_rini: Final KN426 clinical and translational data published @NatureMedicine. The balance of inflammation / angiogenesis impacts….
nature.com
Nature Medicine - Five-year follow-up and prespecified exploratory biomarker analysis from the phase 3 KEYNOTE-426 trial show that pembrolizumab plus axitinib compared to sunitinib as first-line...
0
38
0
RT @ZiadBakouny: Please check out our editorial just out in @NatRevUrol on a pragmatic approach to biomarkers for RCC!. Many challenges, bu….
0
33
0
RT @DrChoueiri: The @ReneeSaliby #kidneycancer biomarker paper in @Cancer_Cell is online with a detailed tweetorial: consistent benefit acr….
0
38
0
RT @TargetedOnc: The phase 3 CheckMate 914 trial revealed that nivolumab did not achieve the primary goal of improving disease-free surviva….
targetedonc.com
In the phase 3 CheckMate 914 trial, the use of nivolumab did not meet the primary endpoint of disease-free survival when compared to a placebo in patients with localized renal cell carcinoma at a...
0
2
0
RT @samirzaidi: Humbled and thrilled to receive the @BWFUND CAMS. I am excited to meet these incredible awardees. Thanks to all my mentors….
0
6
0
RT @DrChoueiri: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest t….
0
24
0
RT @ZiadBakouny: A smaller difference by the number of cycles received, likely not accounting for the absence of an effect in the overall t….
0
3
0
RT @ZiadBakouny: Dr. @motzermd with an important presentation of #CHECKMATE914 Part A subgroup analyses. @ASCO #ASCO23. While the overall t….
0
16
0
RT @ChungHanLee3: Ab#4518 #ASCO23 @ASCO @KidneyCancer . Phase 2 results of lenvatinib + pembrolizumab in pts with non-clear cell #kidneycan….
0
15
0
RT @montypal: RR continue to climb in @ChungHanLee3 @motzermd @MSKCancerCenter trial of cabo/nivo in nccRCC. Need to establish role of TKI/….
0
6
0
RT @DrChoueiri: 1/ Results from #COSMIC-313 are out @NEJM: 1st triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). In….
0
173
0
RT @MSK_DeptOfMed: Congrats to @motzermd and team on their recent study in @NEJM! Phase 3 results showed progression-free survival for peop….
nejm.org
The efficacy and safety of treatment with cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal-cell carcinoma are unknown. In this phase 3,...
0
4
0
0
7
0
RT @DrTHut: @tompowles1 @DrChoueiri @brian_rini @motzermd And your missing the best, the 4 year OS eat al. From the CLEAR trial that I am p….
0
1
0
RT @montypal: Huge congrats to @DrChoueiri & team for paving the way towards a new regimen for #kidneycancer in this @TheLancetOncol paper!….
0
18
0
RT @kcCURE: Dr. Martin Voss from @MSKCancerCenter, 2021 KCCure #chromophobe research grant recipient, updated pts on the potential of IL-15….
0
8
0
RT @EUplatinum: Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated w….
0
11
0
RT @tompowles1: With @YujiMiura5 in the renal cancer session in 🇯🇵 . PD-1/VEGF combos ⬆️ RR in papillary RCC. Dr Juninho Inokuchi thinks t….
0
10
0
RT @DrChoueiri: 1/ Excited to announce updates from the #CLEAR trial in @TheLancetOncol: A long-term follow-up of lenvatinib + pembrolizuma….
0
60
0
RT @EUplatinum: Current Issue: Progression-free Survival After Second Line of Therapy for Metastatic ccRCC in Patients Treated with First-l….
0
6
0